Fig 1.
Flow chart of this study.
Fig 2.
The effect of TAC+5-Fu injection therapy.
TAC+5-Fu injection reduced (a) thickness and (b) elastic modulus of keloids measured by Doppler ultrasound. ****p < 0.0001.
Fig 3.
Baseline difference testing between the experimental group and the control group.
There was no significant difference between two groups in terms of (a) lesions’ thickness or (b) ultrasonic elasticity. NS, p > 0.05.
Table 1.
Demographic information of recruited patients and keloids.
Fig 4.
90Sr prevent keloid from recurrence after injection treatment.
(a) relapse analysis of experimental and control groups. (b) ultrasonic tissue thickness comparison between the two groups measured at 6-month post-brachytherapy or before (relapsed). (c) ultrasonic elastic modulus comparison between the two groups measured at 6-month post-brachytherapy or before (relapsed). **p < 0.01; ***p < 0.001; ****p < 0.0001.
Fig 5.
The effect of 90Sr brachytherapy.
90Sr brachytherapy did not affect (a) the lesions’ thickness or (b) elastic modulus post-injection. NS, p > 0.05.
Fig 6.
A praecordial keloid scar in a 25-year-old women before treatment and 16 months after TAC+5-Fu injection followed by 90Sr brachytherapy. Case 2. A scapular keloid scar in a 23-year-old women before treatment and 14 months after TAC+5-Fu injection followed by 90Sr brachytherapy. Case 3. A praecordial keloid scar in a 22-year-old women before treatment and 17 months after TAC+5-Fu injection followed by 90Sr brachytherapy. Scale bar, 2cm.